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Abstract
Introduction: To raise awareness among health care workers of the risk of withdrawal symptoms
after longstanding and intense abuse of gamma-hydroxybutyric acid.
Case presentation: A 23 year old Caucasian woman presented with gamma-hydroxybutyric
addiction and withdrawal syndrome. The symptoms of gamma-hydroxybutyric withdrawal in this
patient initially went unrecognized, upon which her situation deteriorated in such a way that she
needed to be admitted to the Intensive Care Unit for airway protection and mechanical ventilation.
Treatment with high doses of benzodiazepines led to liberation of the ventilator and further
recovery.
Conclusion: Withdrawal symptoms of gamma-hydroxybutyric addiction are often not well
recognized and the responsible physicians at Emergency Department, Intensive Care Unit and the
Psychiatry ward need better understanding of diagnose and treatment. Gamma-hydroxybutyric acid
withdrawal is potentially life threatening and its management may require a multidisciplinary
approach. Early recognition of gamma-hydroxybutyric acid withdrawal may lead to better
management of these patients.
Introduction
The former anaesthetic gamma-hydroxybutyric acid (GHB;
sodium oxybate), has developed into a popular and
widely used psychoactive party drug. It is easily produced
and often sold in bottles as a liquid. GHB can lower
inhibitions, create feelings of euphoria, and increase
libido. Misuse of GHB may lead to acute loss of
consciousness and subsequent visits to the Emergency
Department (ED). Death as a result of misuse has been
reported [1]. It is less known however that GHB can induce
tolerance and dependence and therefore addiction. Cessa-
tion of GHB use after prolonged abuse may lead to
withdrawal symptoms, [2] and may even be lethal [3]. As
there only are few case reports on GHB withdrawal
syndrome, this syndrome is not yet well known and
therefore difficult to diagnose.
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neurotransmitter gamma-aminobutyric acid (GABA), [4]
with preference for the GABAb receptor. This may explain
why its psychotropic effects resemble those of alcohol and
benzodiazepines (euphoria, amnesia, drowsiness, reduced
anxiety, loss of motor control) and ecstasy (enhanced
sensuality, emotional warmth) [5]. GHB also exhibits
modulating effects on the dopaminergic systems and it
may thus induce extra pyramidal signs. Physical effects are
nausea, vomiting, bradycardia, hypothermia, hypernatre-
mia and metabolic alkalosis.
Therapeutically it has been used in anaesthesia. As it has
only minimal analgesic effects and the potential to
provoke myoclonias, its use in anaesthesia has been
abandoned [6]. Another therapeutic effect is to limit the
symptoms of alcohol withdrawal [7]. GHB also influences
the serotonergic pathways, [8] and it is used to treat sleep
disorders, mainly to diminish cataplexy in narcolepsy [9].
Initial GHB withdrawal features are similar to those for
alcohol: tachycardia, delirium, hallucinations, paranoid
psychosis, autonomic instability, disturbed behaviour,
anxiety, tremor, and restlessness [6,10]. As time progresses,
choreatic movements of extremities and restlessness of the
tongue become prominent, resembling Huntington’s
disease or tardive dyskinesias. Studying the literature, it
becomes evident that there is a large variation in
withdrawal symptoms [10]. The symptoms are a result of
a GABA-depletion as a consequence of GHB dependence.
GHB is rapidly cleared, and dependency can only develop
with sustained levels of GHB, which requires intake every
1-3 hours. Acute GHB withdrawal syndrome is difficult to
diagnose and may lead to life-threatening complications,
as is demonstrated in the following case report.
Case presentation
A 23-year-old Caucasian woman was presented at the ED
of our hospital after having lost her consciousness in a bus.
Bystanders reported convulsions during this event. At our
ED, the woman was too weak and too confused to answer
questions, therefore taking a correct history was not
possible. Her medical records showed substance abuse:
cocaine, cannabis, amphetamines, crack and GHB. At time
of presentation at the ED, she was awake, but with
diminished consciousness and incoherent thoughts,
which was scored as a Glasgow Coma Score (GCS) of
14. Except for tachycardia, vital signs and electrocardio-
graphy were normal.
She was diagnosed with GHB intoxication and admitted to
the medical ward for observation because her conscious-
ness was still slightly lowered. The evening of the day of
admittance, she became very agitated, had hallucinations
and recognized no persons other but her boyfriend. Vital
signs remained stable. Lorazepam was started at 1 mg 4
times per day and raised to 1 mg 6 times per day. As the
agitation increased, she had to be physically restrained.
Being still uncooperative, she received 5 mg haloperidol
and 50 mg clorazepate.
The next day she remained disoriented and still had
hallucinations. Because of her uncooperative behaviour,
she was transferred to the psychiatry ward, next to, but
separated from the hospital, where she was treated with
clorazepate 50 mg daily, oxazepam 25 mg 3 times per day,
biperiden 2 mg 2 times per day and haloperidol in a rising
dose up to 5 mg 3 times per day.
Six days later, her psychiatrist sent her back to the ED
because of deterioration with loss of motor control and
fever. The patient was again very agitated. Physical
examination showed no abnormalities and neither did a
computer tomography (CT) of the brain. At that time she
had a fever of 39.3 °C, a blood pressure 109/76 mmHg,
and a pulse rate of 132/min. Pulse oximetry showed an
oxygensaturationof97%,whileherrespiratoryratewas33/
min and she now scored a GCS of 10 out of 15 (E2 M5 V3).
Laboratory investigation showed WBC 20.000/μl, C-reac-
tive protein (CRP) 50 mg/dl and a highly increased
creatinekinase (CK) of 6000 U/l. Again she was admitted
to the medical ward for observation and treatment with
lorazepam. The next day, the situation worsened with
hypoxia (pO2=8.2 kPa), a rising CK (9800 U/l) and
extreme motion restlessness of extremities with choreatic
movements and peri-oral hyperkinesias. The choreatic
movements, resembling Huntington’s disease, prompted
us to consider a cause related to the GABA system, leading
eventually to the diagnosis of GHB withdrawal syndrome.
Bruises were visible on knees and elbows. With the
diagnosis of severe GHB withdrawal syndrome and
rhabdomyolysis she was admitted to the Intensive Care
Unit (ICU). The midazolam (50 mg/h) and clonidine
(120 mcg/h) needed to manage the unrest, inhibited
patient’scoughingreflexesandleadtodiminishedclearance
of secretions of her upper airway, resulting in hypoxia,
which necessitated intubation and mechanical ventilation.
Even despite these high doses of sedatives, she still
sometimes had phases of being awake and sitting upright
inbed.Becauseofrhabdomyolysis,shereceived6Linfusion
fluid intravenously per 24 hours. There were no signs of
renal failure at any time. After three days the neurological
situation had improved significantly. The patient was
extubated despite having need of high doses of midazolam
and clonidine, which could be decreased over days.
Temperature, CK, WBC and CRP returned to normal values.
Eight days after admission to the ICU, the patient was
discharged to the medical ward with oxazepam 80 mg 3
times perday. Soon thereaftershecould bedischargedfrom
the hospital, without any obvious neurological sequelae.
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Cases Journal 2009, 2:6530 http://casesjournal.com/casesjournal/article/view/2/3/6530Herparentslaterreportedthatoverthelastthreemonthsfor
admittance, their daughter was using GHB every two to
three hours. Based on information given by her parents and
other relatives, our patient daily GHB intake was estimated
between 60 and 90 g. Patient later confirmed this.
Discussion
GHB withdrawal syndrome has been reported in a few case
reports. As it is not well known, it may not easily be
recognized. The risk of a withdrawal delirium seems to
depend on daily dose of ingestion of GHB and duration of
withdrawal [10]. Our patient carried a bottle of liquid
GHB with a concentration of 500 g/L (50% g/v). Years of
use or co-ingestants do not have any influence on the
presence or absence of a delirium [10]. Complications of a
GHB withdrawal are delirium, rhabdomyolysis with
myoglobinuria, and Wernicke’s encephalopathy, severe
muscle spasms and cardiac arrest [3].
Differential diagnosis of GHB withdrawal includes neuro-
leptic malignant syndrome, serotonergic syndrome, cata-
tonia, alcohol withdrawal syndrome, delirium tremens,
steroid psychosis and acute MDMA intoxication. As GHB
influences the dopaminergic pathways, the underlying
mechanism of acute GHB withdrawal might be related to
neuroleptic malignant syndrome.
For the treatment of a GHB withdrawal, benzodiazepines
(diazepam, lorazepam), often in high doses, are recom-
mended [6]. Benzodiazepines are indirect GABAa agonists,
by increasing the receptor affinity for GABA [3]. As GHB
has a preference for the GABAb, this may explain why in
cases of severe GHB addiction, even high doses of
benzodiazepines will not be sufficient to control with-
drawal symptoms. In that event, a combination with
anticonvulsants or non-benzodiazepine sedatives (barbi-
turates, chloral hydrate) is needed [6,7,11]. Clonidine may
be used to diminish the sympathetic symptoms as
tachycardia and sweating. Severe withdrawal lasts 8 to 10
days [10]. Controversial benefit is reported from butyr-
ophenone anti-psychotics like haloperidol. Glasper et al.
report a case of a patient with GHB withdrawal, which was
treated with droperidol without any side effects [12].
Other authors describe severe side effects after adminis-
tration of butyrophenones like haloperidol or droperidol
[13]. McDonough et al. proposed an algorithm for the
management of GHB withdrawal, [10] as did Rosenberg
et al [13].
Our patient showed delirium, cognitive disturbances,
catatonia, rhabdomyolysis, choreatic movements, fever
and severe agitation. After recognition of the GHB with-
drawal syndrome, and use of high doses of benzodiaze-
pines, she ultimately recovered. This confirms previous
reports on (treatment of) GHB withdrawal syndrome.
Conclusion
GHB withdrawal may lead to life-threatening complica-
tions, as demonstrated in this case report. Next to other
withdrawal symptoms, choreatic movements of limbs and
mouth, may be a hint towards the diagnosis. As there are
only a few case reports on GHB withdrawal, it is not
possible to compare different drug treatment regimes.
Because of the high doses of benzodiazepines that are
often needed, it may be necessary to a hospitalize patients
for treatment, if necessary in the ICU. GHB withdrawal
management often will require a multidisciplinary
approach, and ICU treatment with mechanical ventilation
may be life-saving. Since butyrophenones may worsen the
withdrawal symptoms and cause or worsen rhabdomyo-
lysis, these should probably be avoided in the treatment of
psychosis caused by GHB withdrawal.
List of abbreviations
GCS Glasgow Coma Scale; CK Creatinekinase; CRP
C-reactive protein; CT Computer Tomography; ED Emer-
gency Department; GHB gamma-hydroxybutyric acid; ICU
Intensive Care Unit; MDMA 3,4-methylenedioxymetham-
phetamine; WBC White blood cells;GABA gamma-amino-
butyric acid.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MK wrote the final manuscript, NP collected all details to
provide the case presentation and drafted the first version
of the manuscript, CB initially treated the patient and
initiated the writing of the case report.
References
1. Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA:
Adverse events, including death, associated with the use of
1,4-butanediol. N Engl J Med 2001, 344:87-94.
2. Zvosec DL, Smith SW: Comment on "The abrupt cessation of
therapeutically administered sodium oxybate (GHB) may
cause withdrawal symptoms". J Toxicol Clin Toxicol 2004, 42: 121-
123; author reply 125-127.
3. Dyer JE, Roth B, Hyma BA: Gamma-hydroxybutyrate with-
drawal syndrome. Ann Emerg Med 2001, 37:147-153.
4. Nicholson KL, Balster RL: GHB: A new and novel drug of abuse.
Drug Alcohol Depend 2001, 63:1-22.
5. Galloway GP, Frederick-Osborne SL, Seymour R, Contini SE, Smith
DE: Abuse and therapeutic potential of gamma-hydroxybu-
tyric acid. Alcohol 2000, 20:263-269.
6. Craig K, Gomez HF, McManus JL, Bania TC: Severe gamma-
hydroxybutyrate Withdrawal: A case report and literature
review. J Emerg Med 2000, 18:65-70.
Page 3 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:6530 http://casesjournal.com/casesjournal/article/view/2/3/65307. Gallimberti L, Spella MR, Soncini CA, Gessa GL: Gamma-hydro-
xybutyric acid in the treatment of alcohol and heroin
dependence. Alcohol 2000, 20:257-262.
8. Gobaille S, Schleef C, Hechler V, et al: Gamma-Hydroxybutyrate
increases tryptophan availability and potentiates serotonin
turnover in rat brain. Life Sci 2002, 70:2101-2112.
9. U.S. Xyrem Multicenter Study Group: Sodium oxybate demon-
strates long-term efficacy for the treatment of cataplexy in
patients with narcolepsy. Sleep Med 2004, 5:119-123.
10. McDonough M, Kennedy N, Glasper A, Bearn J: Clinical features
and management of gamma-hydroxybutyrate withdrawal: A
review. Drug Alcohol Depend 2004, 75:3-9.
11. Sivilotti ML, Burns MJ, Aaron CK, Greenberg MJ: Pentobarbital for
severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001,
38:660-665.
12. Glasper A, McDonough M, Bearn J: Within-Patient Variability in
Clinical Presentation of Gamma-Hydroxybutyrate Withdra-
wal: A Case Report. Eur Addict Res 2005, 11:152-154.
13. Rosenberg MH, Deerfield LJ, Baruch EM: Two cases of severe
gamma-hydroxybutyrate withdrawal delirium on a psychia-
tric unit: recommendations for management. Am J Drug Alcohol
Abuse 2003, 29:487-496.
Page 4 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:6530 http://casesjournal.com/casesjournal/article/view/2/3/6530
Do you have a case to share?
Submit your case report today
￿ Rapid peer review
￿ Fast publication
￿ PubMed indexing
￿ Inclusion in Cases Database
Any patient, any case, can teach us
something
www.casesnetwork.com